Results 21 to 30 of about 231,116 (154)

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy

Scientific Reports, 2022
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC).
Po-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, Yi-Lin Chen, Wan-Li Chen, Kuan-Yu Lin, Chung-Liang Ho, Jeng-Shiuan Tsai, Szu-Chun Yang, Chian-Wei Chen, Yi-Lin Wu, Yau-Lin Tseng, Chao-Chun Chang, Yi-Ting Yen, Chia-Ying Lin, Chien-Chung Lin, Wu-Chou Su   +16 more
doaj   +1 more source

Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis

Journal for ImmunoTherapy of Cancer, 2022
The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph ...
Hao Long, Si Chen, Hui Yu, Wen-Yu Zhai, Ze-Rui Zhao, Yao-Bin Lin, Yi-Zhi Wang   +6 more
doaj   +1 more source

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial [PDF]

, 2013
Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom.
K Walland, N Fenwick, M Iddawela, E Provenzano, Walland, K., Abraham, J. (Janet), Grier, Anna, L Hiller, J Abraham, A Grier, Fenwick, Nicola, Bowden, S. (Sarah), Iddawela, M., Caldas, C., H M Earl, R Champ, S Bowden, J Dunn, Vallier, A. -L., Champ, R., Earl, Helena M., C Caldas, Dunn, Janet A., Hiller, Louise, A-L Vallier, Provenzano, E.   +25 more
core   +2 more sources

Neoadjuvant Approaches to Non-Melanoma Skin Cancer

, 2023
Surgery and external-beam radiation therapy are the primary treatment modalities for locally advanced NMSC, but they can lead to impairment of function and disfigurement in sensitive areas such as the head and neck.
David C. Wilde, Michael K. Wong, Neil D. Gross, Mica E. Glaun   +3 more
core   +1 more source

Breast cancer: Monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography [PDF]

, 2003
Background: Aim of the study was to assess the value of scintimammography using Tc-99m sestamibi in the evaluation of tumor response to neoadjuvant chemotherapy.
Sommer, H., Keßler, M., Tiling, R., Brinkbäumer, K., Hahn, K., Untch, M., Linke, R.   +6 more
core   +1 more source

Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science

ESMO Gastrointestinal Oncology, 2023
Since the introduction of immune checkpoint inhibitors (ICI) a few years ago, we have witnessed unprecedented improvement in survival in hepatocellular carcinoma (HCC).
L.L. Chan, J.W.C. Kung, S.L. Chan
doaj   +1 more source

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis

Frontiers in Oncology, 2022
ObjectiveThe progress of neoadjuvant therapy for resectable locally advanced esophageal cancer has been stagnant. There has been much progress in immunotherapy for advanced esophageal cancer, but the efficacy and safety of neoadjuvant immunotherapy for ...
Jincheng Wang, Kun Zhang, Tianzhou Liu, Ying Song, Peiyan Hua, Shu Chen, Jindong Li, Yang Liu, Yinghao Zhao   +8 more
doaj   +1 more source

Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis

npj Precision Oncology, 2022
Despite limited efficacy of immunotherapy for advanced non-small-cell lung cancer (NSCLC) with driver mutations, whether neoadjuvant immunotherapy could be clinically valuable in those patients warrants further investigation.
Chao Zhang, Hua-Fei Chen, Shi Yan, Lin Wu, Li-Xu Yan, Xiao-Long Yan, Dong-Sheng Yue, Chun-Wei Xu, Min Zheng, Ji-Sheng Li, Si-Yang Liu, Ling-Ling Yang, Ben-Yuan Jiang, Qiu-Xiang Ou, Zhen-Bin Qiu, Yang Shao, Yi-Long Wu, Wen-Zhao Zhong   +17 more
doaj   +1 more source

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study

Frontiers in Oncology, 2022
BackgroundProgrammed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors displayed considerable advantages in neoadjuvant therapy of non-small cell lung cancer (NSCLC), but the specific application of neoadjuvant immunotherapy has not been well ...
Fuqiang Dai, Xiaoli Wu, Xintian Wang, Kunkun Li, Yingjian Wang, Cheng Shen, Jinghai Zhou, Huijun Niu, Bo Deng, Qunyou Tan, Ruwen Wang, Wei Guo   +11 more
doaj   +1 more source

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study

Translational Oncology, 2023
Background: PD-1 blockade has been shown to have promising efficacy and acceptable safety profiles in advanced and metastatic gastric cancer; however, the efficacy and safety of neoadjuvant PD-1 blockade-based immunotherapy plus chemotherapy in locally ...
Xuchen Zhang, Chuantao Zhang, Helei Hou, Yuming Zhang, Peng Jiang, Hai Zhou, Lele Wang, Na Zhou, Xiaochun Zhang   +8 more
doaj   +1 more source